NOVEL PRECISION MOUSE MODELS OF LIVER CANCER
Hosted by Carlos Sanz-García
With the participation of Scott Friedman & Javier Cubero in the Q&A
is Assistant Professor, Oncological Sciences, a member of The Tisch Cancer Institute, and a member of the Precision Immunology Institute at the Icahn School of Medicine at Mount Sinai. Her research is focused on understanding the mechanisms of liver cancer initiation and liver cancer maintenance. Using a sophisticated precision mouse model of cancer, Dr. Lujambio is investigating biomarker-guided, precision therapies for hepatocellular carcinoma (HCC), the most common type of liver cancer. Her laboratory is also interested in the use of functional genomics for the identification of novel therapies and immunotherapies.
Dr. Lujambio is the recipient of numerous honors and awards, including the Damon Runyan-Rachleff Innovation Award, NCI R37 Merit Award for Early State Investigators, and the GE Liver Junior Scientist Award.